UK Markets closed

Spero Therapeutics, Inc. (SPRO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
13.56-0.49 (-3.49%)
At close: 04:00PM EST
13.56 0.00 (0.00%)
After hours: 06:03PM EST

Spero Therapeutics, Inc.

675 Massachusetts Avenue
14th Floor
Cambridge, MA 02139
United States
857 242 1600
http://sperotherapeutics.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees89

Key executives

NameTitlePayExercisedYear born
Dr. Ankit Mahadevia M.D., MBACo-Founder, CEO, Pres & Director966.83k378.6k1981
Ms. Cristina LarkinChief Operating Officer639.36k157.2k1970
Dr. David A. Melnick M.D.Chief Medical Officer647.31kN/A1952
Mr. Satyavrat Shukla C.F.A.Chief Financial OfficerN/AN/A1973
Dr. Thomas R. Parr Jr.Chief Scientific OfficerN/AN/A1954
Ted JenkinsVP & Head of Investor RelationsN/AN/AN/A
Ms. Tamara Lynn Joseph L.L.M., J.D.Chief Legal OfficerN/AN/A1963
Mr. Timothy KeutzerChief Devel. OfficerN/AN/A1968
Dr. Melissa StundickSr. VP of Bus. Devel.N/AN/AN/A
Dr. Troy Lister Ph.D.Sr. VP of R&DN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. Its product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. Spero Therapeutics, Inc. has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company is headquartered in Cambridge, Massachusetts.

Corporate governance

Spero Therapeutics, Inc.’s ISS governance QualityScore as of 1 July 2021 is 9. The pillar scores are Audit: 10; Board: 7; Shareholder rights: 10; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.